Pulmonary Hypertension in Obese Mice Is Accompanied by a Reduction in PPAR-γ Expression in Pulmonary Artery

Pulmonary Hypertension in Obese Mice Is Accompanied by a Reduction in PPAR-γ Expression in Pulmonary Artery

Obesity and insulin resistance (IR) are well-studied risk factors for systemic cardiovascular disease, but their impact on pulmonary hypertension (PH) is not well clarified. This study aims to investigate if diet-induced obesity induces PH and if peroxisome-proliferator-activated receptor (PPAR-γ) a...

Full description

Bibliographic Details
Main Authors:	Any Elisa de Souza Schmidt Gonçalves, Guilherme Zweig Rocha, Rodrigo Marin, Rafael Ludemann Camargo, Andrey dos Santos, Helison do Carmo, Dioze Guadagnini, Orlando Petrucci, Zenaide Providello Moysés, Vera Maria Cury Salemi, Alexandre Gabarra Oliveira, Mario José Abdalla Saad
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-09-01
Series:	Frontiers in Endocrinology
Subjects:	obesity insulin resistance pioglitazone PPAR-γ high-fat (HF) diet
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2021.701994/full

Similar Items

Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
by: Ivan Ramirez-Moral, et al.
Published: (2021-08-01)

Sex-Based Selectivity of PPARγ Regulation in Th1, Th2, and Th17 Differentiation
by: Hong-Jai Park, et al.
Published: (2016-08-01)

Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes
by: Marcelle Silva-Abreu, et al.
Published: (2017-11-01)

NRF2 and PPAR-γ Pathways in Oligodendrocyte Progenitors: Focus on ROS Protection, Mitochondrial Biogenesis and Promotion of Cell Differentiation
by: Chiara De Nuccio, et al.
Published: (2020-09-01)

PPAR-γ agonist pioglitazone improves semen quality and testicular histomorphometrics with partial reversal of hyperglycaemia in alloxan-induced diabetic rats
by: O.B. Akinola, et al.
Published: (2015-12-01)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
by: Chi-Hung Liu, et al.
Published: (2020-01-01)

Activated PPARγ Abrogates Misprocessing of Amyloid Precursor Protein, Tau Missorting and Synaptotoxicity
by: Susanne Moosecker, et al.
Published: (2019-06-01)

Corrigendum: Activated PPARγ Abrogates Misprocessing of Amyloid Precursor Protein, Tau Missorting and Synaptotoxicity
by: Susanne Moosecker, et al.
Published: (2020-11-01)

Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload
by: Wen-Ying Wei, et al.
Published: (2017-12-01)

Effect of pioglitazone treatment in a patient with secondary multiple sclerosis
by: Pershadsingh Harrihar A, et al.
Published: (2004-04-01)

Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ
by: Pingping Xia, et al.
Published: (2018-03-01)

PPAR-γ Modulators as Current and Potential Cancer Treatments
by: Tiange Chi, et al.
Published: (2021-09-01)

Cytosolic and nuclear distribution of PPARγ2 in differentiating 3T3-L1 preadipocytes
by: Philippe Thuillier, et al.
Published: (1998-12-01)

Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated Hepatitis
by: Rike Schulte, et al.
Published: (2020-04-01)

Celecoxib inhibits acute edema and inflammatory biomarkers through peroxisome proliferator-activated receptor-γ in rats
by: Gholamreza Houshmand, et al.
Published: (2020-12-01)

Ellagic acid potentiates insulin sensitising activity of pioglitazone in L6 myotubes
by: Rakesh P. Nankar, et al.
Published: (2015-05-01)

Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
by: Fatemeh Namvaran, et al.
Published: (2013-01-01)

Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats
by: Zijian Wang, et al.
Published: (2019-10-01)

Enhancement of cognitive functions by rice bran extract in a neuroinflammatory mouse model via regulation of PPARγ
by: A.O. Mostafa, et al.
Published: (2018-09-01)

Pioglitazone Reduces β Amyloid Levels via Inhibition of PPARγ Phosphorylation in a Neuronal Model of Alzheimer’s Disease
by: Qiankun Quan, et al.
Published: (2019-07-01)

Potential of Natural Products in the Inhibition of Adipogenesis through Regulation of PPARγ Expression and/or Its Transcriptional Activity
by: Shi Feng, et al.
Published: (2016-09-01)

Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model
by: Amandeep Mahal, et al.
Published: (2018-07-01)

PPARα and PPARγ as main regulators of fatty acid metabolism
by: Mirosław Kucharski, et al.
Published: (2018-10-01)

The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
by: Pallavi R. Devchand, et al.
Published: (2018-10-01)

PGC-1α Signaling Increases GABA(A) Receptor Subunit α2 Expression, GABAergic Neurotransmission and Anxiety-Like Behavior in Mice
by: Taavi Vanaveski, et al.
Published: (2021-02-01)

Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model
by: Yuji Nakano, et al.
Published: (2020-07-01)

Selective Tissue Distribution Mediates Tissue-Dependent PPARγ Activation and Insulin Sensitization by INT131, a Selective PPARγ Modulator
by: Xinni Xie, et al.
Published: (2017-05-01)

DHA increases adiponectin expression more effectively than EPA at relative low concentrations by regulating PPARγ and its phosphorylation at Ser273 in 3T3-L1 adipocytes
by: Jia Song, et al.
Published: (2017-08-01)

Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease
by: Carmen Ciavarella, et al.
Published: (2020-04-01)

Functional Regulation of PPARs through Post-Translational Modifications
by: Reinhard Brunmeir, et al.
Published: (2018-06-01)

EFFECTIVENESS OF TREATMENT WITH PІOGLITAZONE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT METABOLIC SYNDROME DEPENDING ON PRESENCE RS 1801282 (PRO12ALA) POLYMORPHISM IN GENE PPAR-γ
by: V.P. Shypulin, et al.
Published: (2019-12-01)

THE MAMMARY EPITHELIAL CELL-SPECIFIC ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)γ IN DMBA-MEDIATED BREAST TUMOURIGENESIS
by: Roche, JENNIFER
Published: (2008)

Thymoquinone, a Dietary Bioactive Compound, Exerts Anti-Inflammatory Effects in Colitis by Stimulating Expression of the Colonic Epithelial PPAR-γ Transcription Factor
by: Balaji Venkataraman, et al.
Published: (2021-04-01)

PPARγ Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium
by: Kalina Duszka, et al.
Published: (2017-11-01)

PPARγ and Cognitive Performance
by: Michele d’Angelo, et al.
Published: (2019-10-01)

The use of CHS-131, a selective PPAR-gamma modulator to treat NAFLD/NASH
by: Joshi, Aditya
Published: (2020)

A proline-type fullerene derivative inhibits adipogenesis by preventing PPARγ activation
by: Megumi Funakoshi-Tago, et al.
Published: (2016-03-01)

The Effect of Chinese Medicine on Lipid and Glucose Metabolism in Acute Myocardial Infarction Through PPARγ Pathway
by: Qian Zhang, et al.
Published: (2018-10-01)

Identification of an irreversible PPARγ antagonist with potent anticancer activity
by: Youyi Peng, et al.
Published: (2020-12-01)

BADGE, a synthetic antagonist for PPARγ, prevents steroid-related osteonecrosis in a rabbit model
by: Na Yuan, et al.
Published: (2018-04-01)